Eli Lilly reports Q3 2026 beat and lifts full‑year revenue outlook while trimming EPS guidance
Eli Lilly posted third‑quarter 2026 revenue of $24.4 billion, up 39% year‑over‑year, and GAAP earnings per share of $7.22. Non‑GAAP EPS was $7.48, beating estimates. The company raised its full‑year 2026 revenue guidance to $91 billion‑$92 billion and adjusted EPS guidance to $35.00‑$36.00 per share, citing strong sales of Mounjaro and Zepbound and offsetting acquisition‑related charges.
Why it matters
The higher revenue outlook reflects accelerating demand for Lilly’s weight‑loss drugs, which could boost future cash flow (the company said). The trimmed EPS range accounts for $4.57 per share of acquired IPR&D charges from recent acquisitions, reducing the near‑term profit forecast.
Key facts
- 1Q3 2026 worldwide revenue was $24.4 billion, an increase of 39% versus Q3 2025. prnewswire.com
- 2GAAP EPS for Q3 2026 was $7.22 per share. prnewswire.com
- 3Non‑GAAP EPS for Q3 2026 was $7.48 per share. prnewswire.com
- 4Full‑year 2026 revenue guidance was raised to $91 billion‑$92 billion. prnewswire.com
- 5Adjusted EPS guidance for 2026 was set to $35.00‑$36.00 per share. prnewswire.com
- 6Acquisition‑related charges added $4.57 per share to Q3 earnings. finance.yahoo.com
Summary written by AlphAI AI Desk from 20 of 36 sources. Not investment advice. Figures are as stated by the linked sources.